Medullary Thyroid Cancer Treatment Market Size, Share and Global Trend By Treatment Type (Chemotherapy, Immunotherapy), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
In February 2016, Exelixis, Inc. and Ipsen Pharma announced the licencing agreement to develop and commercialise cabozantinib, a drug indicated to treat medullary thyroid cancer. Medullary thyroid cancer is a rarer form of thyroid cancer or thyroid carcinoma, originating from the parafollicular cells or C cells (a form of neuroendocrine cells), which aid in the production of the hormone calcitonin.
Medullary thyroid cancer first generally originates as a nodule on the thyroid, which is further evaluated to determine if it is benign or cancerous. If the node is found to be cancerous, then it can be further classified into four types of thyroid cancer: medullary, papillary, Hurthle or follicular cancer.
To gain extensive insights into the market, Request for Customization
Initially, there are no symptoms of medullary thyroid cancer, unless an unusual lump in the neck/throat has been noticed by the patient or someone else and in some instances, the lump is painful to touch. Treatment for medullary thyroid cancer include surgical procedures, thyroidectomy, radiation therapy, systemic therapy, medications and chemotherapy.
The global medullary thyroid cancer treatment market growth is expected to driven by number of factors such as increased prevalence of thyroid cancers, increasing advancements in treatment of medullary thyroid cancers, good prognosis rates in early detection, increasing demand for preventive care leading to early diagnosis and increasing awareness.
According to the American Thyroid Association (ATA), medullary thyroid cancer accounts for 1%-2% of all total thyroid cancers. The American Cancer Society (ACS) estimates that sporadic medullary thyroid cancer occurs in 8 out of 10 diagnoses and is more prevalent in the aging populace than the familial form of medullary thyroid cancer, which has a favorable prognostic outcome.
The factors expected to limit the growth of the global medullary thyroid cancer treatment market includes the associated side effects of treatment, lack of early diagnosis and complications associated with surgeries
Key Players Covered
Some of the major companies that are present in the global medullary thyroid cancer treatment market are AstraZeneca, Millennium Pharmaceuticals, Inc., Sanofi, Eli Lilly and Company, Exelixis, Inc and other prominent players.
SEGMENTATION
SEGMENTATION | DETAILS |
By Treatment Type | · Chemotherapy · Tyrosine kinases receptors inhibitors · Other cytotoxic agents · Immunotherapy |
By Distribution Channel | · Hospital pharmacy · Retail pharmacy · Online pharmacy |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
At present, chemotherapy is anticipated to dominate the treatment type segment in the global medullary thyroid cancer treatment market as therapeutics are the first line of treatment of the disease indication.
Key Insights
- Overview of reimbursement scenario in key countries
- Regulatory overview for key countries
- Pipeline analysis
- Key mergers and acquisitions
Regional Analysis
The global medullary thyroid cancer treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is estimated to dominate the global medullary thyroid cancer treatment market due to a number of factors such as the increasing prevalence of thyroid cancer, increasing research & development, established healthcare system, high medical expenditure and presence of key players. Asia Pacific is the fastest emerging market due to increasing incidences of thyroid cancers, increasing adoption of advanced treatment, increasing awareness of diseases, developing healthcare system and large population pools.
Key Industry Developments
- In September 2018, the FDA grated breakthrough designation to LOXO-292, developed by Loxo Oncology, Inc. for the treatment of small lung cancer and medullary thyroid cancer.
- In January 2019, Eli lily and Company announced the company’s decision to acquire Loxo Oncology, Inc. for US$ 8 Bn.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
